Philadelphia, Pa. -- Despite recent discouraging results, endovascular treatment is still a "reasonable" treatment option for selected patients with acute stroke, according to a commentary in the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
A special article in the August Neurosurgery suggests that the US supply of neurosurgeons is inadequate to meet the demand, while a new study finds no evidence that obesity causes worse outcomes in patients with subarachnoid hemorrhage (SAH), a life-threatening type of stroke.
Endovascular Therapy Does Have Benefits in Some Stroke Patients
In the commentary, Dr. Alexander A. Khalessi of University of California, San Diego, and colleagues provide clinical perspective on endovascular treatment of stroke with large vessel occlusion (LVO). These procedures use nonsurgical endovascular techniques to extract the clot blocking blood flow to the brain. Three recent, highly publicized studies reported that endovascular treatment doesn't improve outcomes, compared to standard care.
"However, endovascular intervention did in fact demonstrate benefit when used in the correct clinical context within these trials," Dr. Khalessi and coauthors write. They note endovascular treatment provided better results in patients with LVO stroke confirmed by imaging studies, and in patients with more severe stroke.
From this perspective, "[C]urrent data strongly support the reasonable offering of endovascular therapy for patients with LVO," the commentators conclude. They urge further studies, building on the results of the previous trials.
US Faces Shortage of Neurosurgeons
In a special article, Dr. William T. Couldwell of University of Utah and colleagues re-evaluate evidence on the necessary supply of neurosurgeons in the United States. A commonly cited figure of one neurosurgeon per 100,000 population -- based on a study from the late 1970s -- appears to be outdated.
The researchers estimate the current ratio at about one per 66,000 population. But that's probably still not enough, as there are currently more than 300 open jobs for neurosurgeons. Based on the rate of new trainees, the researchers estimate it will take three years to meet that demand.
Demand "should be reevaluated by region and subspecialty to consider changes in neurosurgery practice," Dr. Couldwell and coauthors write. They note that many of the current job openings reflect a need for emergency coverage.
No Direct Effect of Body Weight on SAH Survival
A study by Dr. Johannes Platz and colleagues of Johann Wolfgang Goethe-University in Germany looked for evidence of an "obesity paradox," with better survival in SAH patients who are obese or overweight. Upon reviewing more than 700 SAH patients, they found that the rate of good outcomes was slightly lower in patients who were overweight.
After adjustment for other key factors, there was no evidence that body weight affected the changes of favorable outcomes after SAH. The results do suggest that obese patients with SAH may be at higher risk of complications—this, rather than obesity itself, may predispose to worse outcomes. Compared to factors like patient age or the severity of the stroke, the effects of obesity appear "negligible," the researchers conclude.
About Neurosurgery
Neurosurgery, the Official journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical, and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
Journal
Neurosurgery